Elagolix for endometriosis pain is also tied to improved QoL, productivity

  • Pokrzywinski RM & al.
  • Am J Obstet Gynecol
  • 21 Nov 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Improvement in reported endometriosis-rated pain with elagolix is related to improved QoL and productivity among those who respond to the treatment.

Why this matters

  • Symptoms from endometriosis can negatively effect health-related QoL (HRQoL) and productivity.
  • Elagolix, an oral gonadotropin-releasing hormone antagonist, has been shown to manage endometriosis-related pain.

Key results

  • Women enrolled in studies with moderate-to-severe endometriosis-related pain who were clinical responders also experienced a meaningful improvement in QoL score and productivity while nonresponders did not.

Study design

  • Post hoc analysis from 2 Elaris Endometriosis (EM-I and EM-II) phase 3, randomised, placebo-controlled studies.
  • Women with a surgical diagnosis of endometriosis-associated pain (n=1686) were enrolled.
  • Outcomes were measured with validated questionnaires; HRQoL was measured using the Endometriosis Health Profile-30, and productivity was measured using the Health-Related Productivity Questionnaire.
  • Funding: AbbVie, Inc. 

Limitations

  • Some cases of pain may have been misdiagnosed as endometriosis-related pain.